CHA2DS2-VASc Score

Cardiovascular Clinical Decision Rule

CHA₂DS₂-VASc Score for AF Stroke Risk

Stratify ischemic stroke risk in non-valvular atrial fibrillation and determine when oral anticoagulation (DOAC vs VKA) is recommended under ESC, AHA/ACC, and Malaysian CPG guidelines.

Clinical Instructions & Guidelines (ESC 2020 & AHA/ACC/HRS)

Anticoagulation Treatment Decision Thresholds

  1. Male Patients:
    • Score 0: Low risk (~0.2% annual stroke risk). No antithrombotic therapy recommended (Class III Harm).
    • Score 1: Intermediate risk (~1.3% annual stroke risk). Oral anticoagulation should be considered based on individual clinical judgement (Class IIa).
    • Score ≥ 2: High risk (≥2.2% annual stroke risk). Oral anticoagulation (DOAC strongly preferred over Warfarin) is strongly recommended (Class I).
  2. Female Patients (Female Sex as a Risk Modifier):
    • Score 1 (Sex-only): Low risk. Female sex without any other risk factor does NOT confer excess risk. No antithrombotic therapy recommended.
    • Score 2 (1 non-sex factor + female): Intermediate risk. Oral anticoagulation should be considered (Class IIa).
    • Score ≥ 3 (≥2 non-sex factors + female): High risk. Oral anticoagulation (DOAC preferred) is strongly recommended (Class I).
  3. DOAC First-Line Preference: Direct Oral Anticoagulants (Apixaban, Rivaroxaban, Dabigatran, Edoxaban) are preferred over Vitamin K Antagonists (Warfarin) due to lower intracranial hemorrhage rates, except in mechanical prosthetic heart valves or moderate-to-severe mitral stenosis.
  4. Bleeding Risk Assessment: Concurrently assess bleeding risk with the HAS-BLED score to identify and correct modifiable bleeding risk factors (uncontrolled hypertension, labile INRs, NSAID/antiplatelet co-medication, alcohol excess).
Patient Factors

Clinical Criteria

1. Patient Age Chronological age at assessment
0 Points
2. Sex Category Female sex is a stroke risk modifier
0 Points
3. Congestive Heart Failure History Clinical signs/symptoms of HF or documented LVEF ≤40%
+1.0 Point
4. Hypertension History Resting BP >140/90 mmHg on ≥2 occasions or on anti-hypertensives
+1.0 Point
5. Stroke, TIA, or Thromboembolism History Previous ischemic stroke, TIA, or systemic embolus
+2.0 Points
6. Vascular Disease History Prior MI, peripheral artery disease (PAD), or complex aortic plaque
+1.0 Point
7. Diabetes Mellitus Fasting glucose >7.0 mmol/L (126 mg/dL) or on antidiabetic medication
+1.0 Point
✓ Clinical AF risk note copied to clipboard!
Calculation Output

Risk Stratification

CHA₂DS₂-VASc Score
0 / 9 pts
Low Stroke Risk
Low Risk (0 pts)
Adjusted Annual Stroke Rate ~0.2% / year
Oral Anticoagulation (OAC) Not Recommended

💡 Anticoagulation Guidance & Strategy

Score 0 (Male): Truly low thromboembolic risk (~0.2%/year). Guidelines (ESC 2020 / AHA 2023) recommend NO antithrombotic therapy (antiplatelets or anticoagulants). Antiplatelet monotherapy is ineffective for AF stroke prevention and causes bleeding harm.
View Point Score Breakdown
1. Age category0
2. Sex category (Female)0
3. Congestive Heart Failure0
4. Hypertension0
5. Prior Stroke / TIA / TE0
6. Vascular disease0
7. Diabetes Mellitus0
Non-sex Risk Factors0 pts
Total Score0 pts
Prescribing Pearl: When oral anticoagulation is indicated, DOACs (Apixaban, Rivaroxaban, Dabigatran, or Edoxaban) are preferred over Warfarin due to superior safety, predictable pharmacokinetics, and a ~50% lower rate of intracranial hemorrhage. Always check baseline renal function (CrCl via Cockcroft-Gault) for appropriate DOAC dosing.

Frequently Asked Questions

What is the difference between CHADS2 and CHA2DS2-VASc?
The older CHADS₂ score categorized a large proportion of patients as "intermediate risk", leaving clinicians uncertain about anticoagulation. CHA₂DS₂-VASc refines this by incorporating Age 65–74 (+1 pt), Age ≥75 (+2 pts), Vascular disease (+1 pt), and Female sex (+1 pt). This reliably identifies patients who are truly at low risk (Score 0 in males, Score 1 in females) who do not need anticoagulation.
Why is Aspirin (antiplatelet monotherapy) no longer recommended for stroke prevention in AF?
Clinical trials (including ACTIVE-A and BAFTA) demonstrated that aspirin is substantially less effective than oral anticoagulants at preventing cardioembolic ischemic strokes in atrial fibrillation, while conferring a similar risk of major bleeding—especially in elderly patients. Current ESC, AHA/ACC, and NICE guidelines explicitly advise against antiplatelet monotherapy for stroke prevention in AF.
How should bleeding risk be balanced against stroke risk?
A high bleeding risk score (e.g. HAS-BLED score ≥3) is NOT an absolute reason to withhold anticoagulation, because patients at highest bleeding risk are often those at highest stroke risk who derive the greatest net clinical benefit. Instead, a high HAS-BLED score should prompt frequent clinical review and aggressive correction of modifiable bleeding risks (e.g. optimizing blood pressure, stopping unnecessary NSAIDs or antiplatelets, and moderating alcohol).
Does CHA2DS2-VASc apply to patients with mechanical prosthetic heart valves or mitral stenosis?
No. CHA₂DS₂-VASc is specifically validated for non-valvular atrial fibrillation. Patients with mechanical prosthetic heart valves or moderate-to-severe rheumatic mitral stenosis have "valvular AF" and represent a severe thromboembolic risk requiring therapeutic anticoagulation with Warfarin (VKA) regardless of their CHA₂DS₂-VASc score. DOACs are contraindicated in mechanical valves.
Evidence & Guidelines

References

  1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.
  2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.
  3. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156.
  4. Ministry of Health Malaysia. Clinical Practice Guidelines on Management of Atrial Fibrillation.

Medical Disclaimer: This clinical calculator is intended as an educational and bedside decision-support tool for licensed healthcare professionals. Clinical judgement, patient bleeding risk, and individual patient values must be considered before initiating oral anticoagulation.

Scroll to Top